OncoGenex Pharmaceuticals Added to Russell Indexes

BOTHELL, WA and VANCOUVER, British Columbia, June 28, 2011 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients, announced today that the Company was added to the Russell Global Index, Russell 2000® Index, Russell 3000® Index and Russell Microcap® Index at the close of market on June 24, 2011 as part of the annual reconstitution of Russell indexes.

Annual reconstitution of Russell's U.S. indexes captures and ranks the 4,000 largest U.S. stocks as of the end of May. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets currently are benchmarked to them.

Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell Global Index, which captures 98% of investable securities globally, is reconstituted annually and all sub-indexes are recalibrated simultaneously to accurately measure current market realities for each market segment. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 Index is a subset of the Russell 3000 Index representing approximately 10% of the total market capitalization of that index. The Russell 2000 is constructed to provide a comprehensive and unbiased small-cap barometer. The Russell 3000 Index is constructed to provide a comprehensive, unbiased, and stable barometer of the broad market. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value style indexes.

More information about Russell indexes, including total returns, is available at http://www.russell.com/Indexes/data/default.asp.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.  OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information on OncoGenex can be found at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

For further information:

OncoGenex Contact: 
Jaime Welch
(604) 630-5403
jwelch@oncogenex.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890